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Abstract
Alpha1-antitrypsin (AAT) deficiency is a hereditary disorder associated with reduced AAT plasma levels, predisposing adults
to pulmonary emphysema. The most common genetic AAT variants found in patients are the mildly deficient S and the
severely deficient Z alleles, but several other pathogenic rare alleles have been reported. While the plasma AAT deficiency is
a common trait of the disease, only a few AAT variants, including the prototypic Z AAT and some rare variants, form
cytotoxic polymers in the endoplasmic reticulum of hepatocytes and predispose to liver disease. Here we report the
identification of three new rare AAT variants associated to reduced plasma levels and characterize their molecular behaviour
in cellular models. The variants, called Mpisa (Lys259Ile), Etaurisano (Lys368Glu) and Yorzinuovi (Pro391His), showed
reduced secretion compared to control M AAT, and accumulated to different extents in the cells as ordered polymeric
structures resembling those formed by the Z variant. Structural analysis of the mutations showed that they may facilitate
polymerization both by loosening ‘latch’ interactions constraining the AAT reactive loop and through effects on core
packing. In conclusion, the new AAT deficiency variants, besides increasing the risk of lung disease, may predispose to liver
disease, particularly if associated with the common Z variant. The new mutations cluster structurally, thus defining a region
of the AAT molecule critical for regulating its conformational state.
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Introduction
Alpha1-antitrypsin deficiency (AATD) is a genetic disorder
characterized by reduced plasma levels of alpha1-antitrypsin
(AAT), the archetypal member of the serpin (serine protease
inhibitor) protein superfamily. An acute phase glycoprotein, AAT
is mainly synthesized in the liver and it inhibits neutrophil elastase
to regulate inflammatory processes in the circulation and lung
tissue [1,2]. Plasma levels of AAT are tightly linked to variants of
the coding gene SERPINA1 (14q32.1) (OMIM: 107400), which
dictate the AAT concentration according to a co-dominant model.
Pathogenic alleles of the SERPINA1 gene are conventionally
classified as ‘‘null’’, if associated with undetectable AAT, or as
‘‘deficient’’ alleles if the mutated protein is synthesised and
retained in a misfolded state within hepatocytes, resulting in
variable degrees of secretion defect [3].
The commonest deficient variants causing AATD are the S
(Glu264Val) and Z (Glu342Lys) mutations. SS genotypes result in
mild deficiency, with minimal clinical sequelae. The ZZ and SZ
genotypes, associated with 15% and 25% of normal AAT plasma
levels, account for the vast majority of severe AATD. However,
there are several other pathogenic AAT alleles described, usually
referred to as ‘‘rare alleles’’, associated with varying degrees of
reduced plasma level. The prevalence of these rare AATD
genotypes is believed to be more frequent in the Mediterranean
area [4,5].
The deficiency of circulating AAT is associated with an
increased risk of developing emphysema, due to uncontrolled
elastase activity in the lung, which may be exacerbated by
additional risk factors such as cigarette smoke [6]. Besides
emphysema, the Z AAT variant also predisposes to liver diseases,
which may present in ZZ homozygous individuals as neonatal
jaundice, cirrhosis and increased risk of hepatocellular carcinoma
[7]. The development of liver disease is caused by excessive
accumulation of Z AAT in the endoplasmic reticulum (ER) of
hepatocytes as ordered polymeric structures, which deposit in
PAS+, diastase-resistant inclusion bodies [8]. Polymerization of Z
AAT proceeds through formation of an unstable monomeric AAT
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teraction between two AAT motifs, the reactive loop and beta-
sheet A. The latter is opened in M* and insertion of the reactive
loop links two AAT molecules into a dimer. Successive in-
termolecular interactions lengthen this into a polymer chain [11].
Currently three models of serpin polymerization are proposed in
the literature, all of which conform to these constraints, but
differing in the number of beta strands (1, 2, or 3) involved in the
intermolecular linkage [12–15]. However all three models in-
corporate release of strand 1 of beta-sheet C, expansion of beta-
sheet A and insertion of reactive loop residues as an extra strand in
beta-sheet A. Besides the archetypal Z AAT, other deficiency
variants have been shown to form polymers within the ER. While
the Z mutation resides in the hinge region at the base of the
reactive loop, other strongly polymerizing variants such as Siiyama
(Ser52Phe), Mmalton (Phe52del) and King’s (His334Asp) carry
mutations localized in the shutter region, which directly favour
opening of beta-sheet A [16–18]. The Pbrescia mutation instead
perturbs an arginine pocket that normally stabilizes the reactive
loop [19], and milder polymerizing variants such as I (Arg39Cys)
and S (Glu264Val) may act indirectly on beta-sheet A stability by
perturbing helix A/G-core packing [20]. Although the different
mutations affect different AAT regions, the resulting polymers are
recognised by a monoclonal antibody (mAb) specific for Z AAT
polymers, strongly supporting their structural similarity [18].
Here we report the identification and characterization of three
novel AAT alleles, Mpisa (Lys259Ile), Etaurisano (Lys368Glu) and
Yorzinuovi (Pro391His), associated with reduced concentration of
AAT in plasma. The behaviour of the variants when expressed
individually in cellular models clearly supports their identification
as deficiency alleles, with a range of intracellular polymer loads
observed. These mutations cluster structurally and are likely to
facilitate polymerization both by effects upon ‘latch’ interactions
constraining the AAT reactive loop and upon core packing.
Materials and Methods
Subjects
The index case carrying the Mpisa AAT allele was 26 years old
at the time of diagnosis at the San Matteo Hospital (Pavia, Italy).
He had dyspnea and no evidence of liver disease. The index case
carrying the Etaurisano AAT allele was 31 years old when he was
referred to the San Matteo Hospital (Pavia, Italy) because of
panlobular emphysema. The proband with the Yorzinuovi allele
was first admitted at the age of 46 at the Gastroenterology
department of Spedali Civili (Brescia, Italy) because of a ten year
history of mild hyper-transaminasemia. The index case’s families
were investigated where possible. Collection of blood samples and
the genetic investigations were performed after appropriate written
informed consent of the subjects involved and approval by the
ethical committees of the institutions involved (San Matteo
Hospital of Pavia and Spedali Civili of Brescia, Italy). The patients
in this manuscript have given written informed consent to
publication of their anonymised case details.
Quantification of Alpha1-antitrypsin and C-Reactive
Protein (CRP) Plasma Levels
The AAT level measurements were performed on plasma or
dried blood spot (DBS) samples by a rate immune nephelometric
method (Array 360 System; Beckman-Coulter) using a goat anti-
human AAT antibody (Beckman-Coulter) [21]. The CRP level
measurement was performed on plasma samples by an immune
nephelometric assay (Image Immunochemistry System; Beckman-
Coulter).
Figure 1. Genotypes of the index cases. (A) Table summarizing the amino acid mutations of the variants, the genotypes of the index cases as
well as the plasma levels of AAT and C-reactive protein (CRP) determined in the index cases. (B) Pedigree of the Etaurisano proband’s family. (C)
Pedigree of the Yorzinuovi proband’s family. Arrows in the family trees indicate index cases. Half-filled squares and circles indicate heterozygous
subjects.
doi:10.1371/journal.pone.0038405.g001
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The phenotype of the new variants was determined by IEF
analysis on plasma/DBS samples, comparing them with sera of
known phenotype in a pH gradient of 4,2–4,9 (Multiphor II
Electroforesis System, GE Healthcare BioScience) as previously
described [22]. Conventionally, the variants were named
according to their IEF migration and the birthplace of the
senior carrier.
Molecular Studies of New Alpha1-antitrypsin Variants
DNA was isolated from whole peripheral blood or DBS samples
using a commercial extraction kit (DNA IQ System, Promega).
Genotyping for detection of the S and Z variants was performed
by PCR/RFLP, as previously described [23]. The new mutations
were identified by sequencing all coding exons (II-V) of the AAT
gene (SERPINA1, RefSeq: NG_008290), as previously described
[22], using the CEQ 8800 genetic analysis System (Beckman
Coulter). The background of the Mpisa and Yorzinuovi alleles was
determined on the base of the rs709932, rs6647 and rs1303 SNPs.
To determine the background of the Etaurisano variant, the
amplimers of exon V from the index case’s DNA were sub-
sequently cloned into a pCR2.1 vector using the TA Cloning Kit
(Invitrogen), transformed in One Shot InvaF’ E.coli cells and
sequenced by usual protocol.
Construction of Alpha-1 Antitrypsin Expression Vectors
The pcDNA3.1/Zeo (+) expression vectors encoding for human
M1(Val213) and Z AAT [24] were generous gifts from Dr R. Sifers
(Baylor College of Medicine, Houston, TX). The mutations of the
Mpisa, Etaurisano and Yorzinuovi were introduced into the M1
AAT cDNA by site-directed mutagenesis using the QuikChange II
Site-Directed Mutagenesis Kit (Stratagene), according to the
manufacturer’s instructions and with the following primers and
those complementary to them:
Mpisa (59CTGCCTGATGAGGGGATACTACAG-
CACCTG);
Etaurisano (59CCCGAGGTCAAGTTCAAC-
GAACCCTTTGTCTTCTTAA);
Yorzinuovi (59TGGGAAAAGTGGTGAATCACACC-
CAAAAATAACTGCC).
Cell Culture and DNA Transfections
The Hepa 1.6 (IZLER, Brescia, Italy) and COS-7 (ATCC) cells
were grown in DMEM supplemented with 10% FBS (Sigma).
Transient transfections of both cell lines with AAT encoding
vectors were performed with Lipofectamine2000 (Invitrogen)
according to the manufacturer’s protocol, using a 1:3 DNA
(mg)/Lipofectamine (ml) ratio in serum free DMEM for 5 h and
then culturing transfected cells with normal medium for further
24 h. Alternatively, Hepa1.6 cells were transfected by adding to
sub-confluent cells grown in normal culture medium a PBS
solution containing polyethylenimine (PEI ‘‘Max’’, Polysciences
Inc.) and plasmid DNA (20 mg PEI ‘‘Max’’ and 2 mg DNA in
40 ml PBS for 10 cm
2 wells).
Pulse-chase Experiments
Cells were pulsed for 10 min with
35S Met/Cys (EasyTag
TM
Express Protein Labelling mix, Perkin Elmer) and chased for 0, 30,
60, 120 and 240 min. At each point in time, the cell media were
collected and the cells were lysed in a buffer containing 50 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP40, 10 mM NEM and
protease inhibitors (Sigma-Aldrich). The NP40-soluble and -
insoluble fractions from cell lysates were separated by centrifuga-
tion at 12000 g and the insoluble material recovered in the pellet
was solubilised by boiling in 50 mM Tris-HCl, pH 7.4, 2% SDS
and then diluted 1:10 with a buffer containing 50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1% NP40. The radiolabelled AAT in
cell fractions and media was then immunoprecipitated using an
anti-AAT polyclonal antibody (DAKO) and analysed by SDS-
PAGE/autoradiography.
Quantitative Dot Blot
The different AAT variants were expressed in Hepa 1.6 cells by
transfection with Lipofectamine2000 (Invitrogen) as described
above. 24 h after transfection, the culture media were replaced by
serum-free media and cells were further incubated for 16 h. AAT
in the cell media was analysed by dot blot in parallel with serial
dilutions of purified AAT (Sigma), revealed with an anti-AAT
polyclonal antibody (DAKO), HRP-conjugated anti-rabbit anti-
bodies (Amersham) and ECL Plus (Amersham). In one experi-
ment, AAT was revealed by anti-AAT polyclonal antibody
(DAKO), IRDye800CW-conjugated anti-rabbit IgG (Li-cor Bio-
science) and the Odissey FC Imaging System (Li-cor Bioscience).
Dot blots were analysed by densitometry, and the AAT levels were
calculated for each experiment from the AAT standard curve and
expressed as percentages relatively to the mean levels for M AAT.
Statistical analysis was performed by one-way ANOVA followed
by Dunnet’s post-test using GraphPad Prism version 5 (Graphpad
software Inc, San Diego, CA, USA).
Non-denaturing PAGE and Western Blot Analysis
For non-denaturing analysis, the different AAT variants were
expressed in COS-7 cells by transfection with Lipofectamine2000
(Invitrogen) as previously described [25]. 48 h after transfection
culture media were collected and concentrated 10 times in
Vivaspin columns with a 3000 Da cut-off membrane (Vi-
vaScience), while cells were lysed in a NP40 buffer (150 mM
NaCl, 50 mM Tris-HCl pH 7.4, 1% NP40). Both cell lysates and
culture media were subjected to 7.5% non-denaturing PAGE and
blotted as described [25]. Membranes were probed with either the
commercial anti-AAT mAb 704 (Abcam) or with the 2C1 mAb
[18] and revealed with HRP-conjugated anti-mouse antibodies
(Sigma-Aldrich) and ECL SuperSignal West Pico and Femto
Maximum Sensitivity Substrates (Pierce Biotechnology).
Results
Identification of the Novel Alpha1-antitrypsin Alleles
The new AAT variants investigated in this study, as well as the
genotype and plasma concentration of AAT and CRP of the index
cases, are summarised in Figure 1A. The levels of CRP were
Figure 2. Fate of the new AAT variants in Hepa 1.6 transfected cells. (A) Pulse-chase experiments on Hepa 1.6 cells expressing AAT variants.
Transfected Hepa 1.6 cells were pulsed with
35S Met/Cys for 10 min and chased for the indicated times. AAT was immunoprecipitated from culture
media and from NP40-soluble and NP40–insoluble cell fractions, and analysed by SDS-PAGE and autoradiography. Arrows, mature secreted AAT
(approx. 54 kDa); arrowheads, immature intracellular AAT (approx. 50 kDa). (B) Densitometric analysis of the autoradiograms shown in panel A. The
relative amounts of AAT at the different times are expressed as percentage of the total amount of intracellular AAT at the beginning of chase (time 0),
set as 100%.
doi:10.1371/journal.pone.0038405.g002
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inflammatory state on AAT plasma concentration. The variants
were named according to the plasma protein’s migration by IEF
(M, E and Y; Figure S1) and the birthplace of the senior carrier
(Pisa, Taurisano and Orzinuovi).
TheMpisaalleleischaracterizedbyanAtoTtransitioninexonIII
(c.848A.T) in the M1Val background, resulting in a Lys259Ile
substitution.TheMpisaallelewasidentifiedinassociationwiththeZ
AAT allele in a patient with emphysema and reduced AAT plasma
levels (56 mg/dL). Afterwards, other five M/Mpisa unrelated
subjects were identified. Their AAT plasma levels (82–96 mg/dl)
were at the lowerlimit ofnormal values [26].
The Etaurisano allele is characterized by a transversion in AAT
exon V (c.1174 A.G) resulting in Lys368Glu substitution. It was
first identified in a subject with panlobular emphysema, in the
heterozygous state with the M allele. It was then found in the index
case’s father and brother (Figure 1B). Cloning and sequencing of
exon V indicated that the Etaurisano mutation arose on the M2
background allele.
The Yorzinuovi allele is characterised by a transversion in exon
V (c.1244C.A), resulting in a Pro391His protein mutation, on
a M1Val background. It was first identified in heterozygous state
with M in a subject with mild but persistently elevated trans-
aminase levels, as well as in three related asymptomatic subjects
(Figure 1C). Notably, the Pro391His mutation was previously
found in association with the Asp256Val mutation in the
Ybarcelona AAT variant [27].
More clinical details on the probands are reported in the
Information S1.
Reduced Secretion of the Newly Identified Variants by
Hepa 1.6 Hepatoma Cells
We investigated the molecular behaviour of the novel AATD-
associated variants by expressing them in liver-derived cells
(Hepa1.6) and performing pulse-chase experiments (Figure 2).
As controls we included M and Z AAT, as well as Mwurzburg
(Pro369Ser), a previously described AAT deficiency variant
whose amino acid substitution occurs next to that of Etaurisano
[28]. As expected, the newly synthesized M AAT was present at
the end of the pulse period in the NP40-soluble cell fraction as
a single band of about 50 kD, which corresponds to the high
mannose intermediate form (Figure 2A, arrowhead). During the
chase period, the protein is converted to a fully glycosylated
mature protein (approx. 54 kD) that is rapidly secreted into the
medium (Figure 2A, arrow). Only a small amount of M AAT
was transiently found as immature polypeptide in the NP40-
insoluble cell fraction. On the other hand, the newly synthesized
Z protein was mainly retained in the cells as immature and
significantly accumulated in the NP40-insoluble fractions,
confirming its tendency to form large insoluble complexes
(Figure 2A). The novel variants showed a reduction of protein
secretion and were found in the NP40-insoluble fraction,
suggesting that they formed large insoluble intracellular com-
plexes similarly to Z AAT, although to different extents. The
AAT distribution at different time points in the intracellular
soluble and insoluble fractions, as well as in the cell media, was
quantified by densitometry and expressed as percentages of the
total AAT amount found at time 0 of chase (Figure 2B). At
240 min of chase, when about 78% of the wild-type M is found
in the culture medium, the different mutants show reduced
secretion (Z 16%, Mwurzburg 27%, Etaurisano 52%, Mpisa
22% and Yorzinuovi 11%). At the same time point, when the
wild-type M is undetectable in the NP40-insoluble fraction, all
the mutants show an accumulation of detergent insoluble
complexes (Z 21%, Mwurzburg 13%, Etaurisano 13%, Mpisa
13% and Yorzinuovi 43%).
Figure 3. Secretion of the AAT variants relative to M AAT. (A)
Dot blot analysis of AAT secreted in the cell media by Hepa 1.6 cells
expressing Null-hk, M, Z, Mwurzburg, Mpisa, Etaurisano or Yorzinuovi.
The right panel shows serial dilutions of purified AAT. (B) AAT secreted
in the cell media of transfected Hepa1.6 cells, expressed as percentage
of M AAT. Dot blots performed as shown in panel A were analysed by
densitometry, AAT levels were calculated from the purified AAT
standard curve, and expressed as percentages of M AAT level. The
results are presented as means and SD of three independent
transfection experiments (each experiment in duplicates). Asterisks
indicate statistical significance (p,0.01 by Dunnett’s test of each variant
compared to M AAT). Null-hk and Yorzinuovi were ,10% of M AAT.
doi:10.1371/journal.pone.0038405.g003
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steadystatebyquantitativedot-blotanalysisoftheAATfoundincell
culture media of transfected Hepa1.6 cells (Figure 3). Panel A
represents a single experiment comparing the different mutant
variants and the M, Z and Null-hongkong (Null-hk) controls, using
serial dilutions of commercial purified AAT (Sigma) as reference.
Quantitative densitometric analysis of dot blots from three in-
dependent transfection experiments (Figure 3B) confirmed the
results of the pulse chase experiments showing that the new
deficiency variants all behave as defective in Hepa 1.6 cells, the
Yorzinuovi being the most severely deficient (below 10% of M
AAT).
Formation of Polymers by the Alpha1-antitrypsin Variants
in Transfected COS-7 Cells
The finding that the new variants accumulated as large NP40-
insoluble complexes in Hepa 1.6 cells prompted us to investigate
whether their accumulation occurs in the form of ordered
polymers, similarly to Z AAT. We assessed the presence of AAT
polymers in cell lysates and culture media from COS-7 cells
transiently expressing the variants by non-denaturing PAGE and
immunoblot analysis (Figure 4). As expected, M AAT was found at
low levels within the cells and was secreted in the cell medium
exclusively in the monomeric form. Z AAT instead was found
mainly as polymers both in the cell lysate and in the medium.
Similarly, polymeric AAT was found in both the cell lysates and
media of the cells expressing the new variants (Figure 4, middle
panels). Variable proportions of the monomer and polymer forms
are detected for the different AAT variants, in correlation with
their propensity to polymerize. This is consistent with previous
studies on alpha1-antitrypsin and neuroserpin mutants [18,25,29].
The Mwurzburg and Etaurisano variants displayed a higher
percentage in the monomeric form, in agreement with their milder
defect in secretion. Based on our results, we cannot determine
whether the polymers found in the cell media are formed
extracellularly, secreted from the cells or both. The polymeric
forms were all recognised by the polymer specific mAb 2C1 [18]
(Figure 4, bottom panels), suggesting that the polymers formed by
the new variants of AAT structurally resemble those formed by Z
AAT. Analysis of intracellular and extracellular AAT variants by
sandwich ELISA with the 2C1 mAb [30] confirmed the presence
of Z-like polymers in all the samples produced by transient
expression of the new AAT variants in COS-7 cells (results not
shown).
Figure 4. Intracellular accumulation of the new AAT variants as 2C1-positive polymers. PAGE and immunoblot analysis for AAT in NP40–
soluble cellular fractions (C) and culture media (M) from COS-7 cells transfected with M, Z, Mwurzburg, Mpisa, Etaurisano and Yorzinuovi AAT cDNAs
or empty vector (-). Top panels: reducing SDS-PAGE and immunoblot with the 704 mAb to AAT (Abcam). Middle panels: non-denaturing PAGE and
immunoblot with the 704 mAb (Abcam). Bottom panels: non-denaturing PAGE and immunoblot with the 2C1 mAb specific for AAT polymers. The
middle and bottom panels correspond to the same membranes probed first with the 2C1 mAb and then with the 704 mAb from Abcam.
doi:10.1371/journal.pone.0038405.g004
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We have assessed likely structural effects of the new mutations
(Figure 5). They cluster in the so-called ‘gate’ region of AAT [31],
where a network of hydrophobic interactions fasten the lateral
border of b-sheet C to close a b-barrel motif with b-sheet B. The
Yorzinuovi, Etaurisano and Mwurzburg mutations loosen this
interaction to facilitate release/prevent tethering of strand 1 of b-
sheet C (s1C) and favour mobilisation of the reactive site loop to
adopt alternative conformations (Figure 5A). The Mpisa (Ly-
s259Ile), Etaurisano (Lys368Glu) and Mwurzburg (Pro369Ser)
mutations will also perturb helix G, affecting core packing and
hence the shutter region.
AAT is the archetype of the serine protease inhibitor (serpin)
superfamily [32]. We performed protein sequence alignment of
a range of inhibitory serpins [33] to assess the overall conservation
of the aminoacids mutated in the new variants. The Yorzinuovi
(Pro391His), Etaurisano (Lys368Glu) and Mwurzburg (Pro369Ser)
mutations affect highly conserved C-terminal residues (Figure 5B),
further supporting the hypothesis that they play a crucial role in
the folding, stability and function of serpins.
Discussion
In this study we report three new AAT deficiency variants,
bearing non-conservative aminoacid substitutions, that we named
Mpisa (Lys259Ile), Etaurisano (Lys368Glu), and Yorzinuovi
(Pro391His). These variants were identified in Italian patients
with reduced serum AAT levels. The previously reported variant
Mwurzburg was included in our study because the causative
mutation (Pro369Ser) affects the adjacent residue to that affected
in Etaurisano (Lys368Glu). Moreover, this variant is represented
in the Italian cohort of AATD patients with rare alleles (LC and
ML, unpublished data) and allows us a further correlation between
mutations in this region and cell model data. We studied both
intracellular accumulation and defective secretion of AAT in our
cell models since these respectively relate to the major pathogenic
drivers of the liver and lung disease associated with AAT
deficiency.
The new variants show a secretion defect in Hepa cells, the
Yorzinuovi being the most severely deficient. These in vitro results
are fully consistent with the plasma levels observed in the carriers,
while clinical evidence of lung disease was established only in some
patients. The onset of emphysema indeed depends on several risk
factors, particularly cigarette smoke, as widely documented for Z
homozygous individuals [6].
We also evaluated the tendency of the different variants to
form ordered polymers when expressed in transfected Hepa and
COS cells. The higher tendency to form polymers was displayed
by Yorzinuovi, which explains its severe secretory defect. Based
on the recognition by the 2C1 polymer-specific monoclonal
antibody, the structure of the polymers formed by the new
variants resembles that of Z. The index case carrying the
Yorzinuovi allele in association with the wild-type M allele was
referred because of persistently elevated transaminases, although
no AAT inclusions were evidenced by immunohistochemical
analysis on liver biopsy, while the two other carriers of this
allele were fully asymptomatic. This mild phenotype may be
related to the heterozygote state of the carriers. Similarly the
MZ phenotype is not associated with severe lung or liver
disease. Indeed, even the ZZ phenotype is associated with a wide
spectrum of liver disease: from disease-free to end-stage hepatic
failure or malignancy. Thus the risk of liver disease from
intrahepatocytic polymerization is modified by further genetic
and environmental factors, only partially elucidated.
Sequence alignment of different serpins revealed that the
aminoacids mutated in the Etaurisano, Mwurzburg and Yorzi-
nuovi are in a highly conserved C-terminal region, likely to be
important for the structural stability of serpins. Consistently, other
natural mutations leading to plasma deficiency have been reported
to affect this region. The Pro391His mutation was previously
found in association with the Asp256Val mutation in the
Ybarcelona AAT variant [27]. Pro369 is also mutated in the
Mheerlen AAT deficient variant (Pro369Leu) [28,34]. Moreover,
the Pro476Ser substitution in the C1 inhibitor (equivalent to
Pro391 in the AAT) was previously reported to promote
intracellular multimerization, causing reduced plasma levels and
angioedema [35].
The crucial role of the C-terminal AAT region is strengthened
by our structural analysis aimed at predicting the possible effects of
the mutations underlying intracellular accumulation and polymer
formation. The mutations highlight the structural significance of
the gate region of AAT, where a network of hydrophobic
interactions fasten the lateral border of b-sheet C to close a b-
barrel motif with b-sheet B. Since these interactions keep the gate
region closed in the native structure we propose they be termed
‘latch’ interactions. Loosening these interactions will favour
‘unlatching’ of the gate and population of the polymerogenic
intermediate M* (Figure 5A). An opened gate [31] and untethered
s1C [36] have both previously been proposed as requirements for
conformational change in the serpin superfamily. The new
mutations show these are likely intrinsically coupled during
intracellular polymerisation. The network of latch interactions
also explains the elegant systematic mutagenesis study of Pro391
carried out almost two decades ago [37]. Mutation to hydrophobic
residues had minimal effects on secretion and degradation profiles.
However as mutations became increasingly hydrophilic, intracel-
lular retention within the ER and/or degradation increased to give
phenotypes more marked than the Z variant.
The mutations also highlight the significance of packing
interactions between a-helices A and G and b-sheet B within the
core of the molecule. Destabilisation of such interactions and
consequent dysregulation of b-sheet A opening has been
postulated as the mechanism by which the S (Glu264Val) [38]
and I (Arg39Cys) [20] mutations cause polymerisation and mild
plasma deficiency. The Mpisa (Lys259Ile) mutation will affect G-
helix packing whilst the linker preceding the G-helix will be
destabilised by the Etaurisano (Lys368Glu) mutation. Formation
of the intermediate state in either the single strand (‘classical’ loop-
sheet model [12,13]) or triple strand (C-terminal derived [15])
linkage models of serpin polymerization are highly consistent with
direct coupling of s1C release with intramolecular loop insertion.
Both of these models are therefore similarly compatible with the
finding that gate loosening and/or core disrupting mutations result
in increased polymerization and mild deficiency. In contrast, gate
opening does not appear integral to the 2 strand (beta-hairpin
[14]) model. It seems less likely that the ‘latch’ mutations we
describe would trigger polymer formation by this mechanism.
Further structural studies will be required to establish whether the
novel variants populate extensively unfolded intermediates in the
disease state, as proposed in the triple-strand model, or favour
more parsimonious conformational change, consistent with single-
strand linkage. In conclusion, we demonstrate that the new AAT
deficiency variants, besides increasing the risk of lung disease, may
predispose to liver disease, particularly if associated with Z or with
a different polymerogenic variant. Together the novel mutations
define a latch region that regulates the population of an M* state.
Polymerogenic mutations here will promote conformational
change by favouring s1C release and/or effects upon core packing.
Rare a1-Antitrypsin Variants and Polymerization
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38405Figure 5. Structural analysis of the new alpha1-antitrypsin mutations. (A) Upper panel: Mutation sites in native AAT (PDB ID: 1QLP; b-sheet
A in blue, reactive loop red, B/C sheet b-barrel yellow, mutation site residues in pink, zoom is rotated 90u around vertical axis). ‘Latch’ interactions
(dotted lines) stabilise the closed conformation of the ‘gate’ (s4C-s3C). Lower panel: left, gate closure in the native state; right, gate opening is
associated with loss of latch interactions, release of s1C and conformational change (intermediate state modelled upon latent conformer, PDB ID:
1IZ2, [39]). (B) Alignment of C-terminal sequences of inhibitory human serpins, performed by ClustalW2 (www.ebi.ac.uk, default parameters, visualised
by Jalview). SERPINA1, a1-antitrypsin; A3, a1-antichymotrypsin; A4, kallistatin; A5, PAI3; A10, protein Z-dependent protease inhibitor; B1, leukocyte
elastase inhibitor; B2, PAI2; C1, antithrombin III; D1, heparin cofactor 2; E1, PAI1; E2, glia-derived nexin; F2, a2-antiplasmin; G1, C1 inhibitor; I1,
neuroserpin. Alpha1-antitrypsin mutation sites of Z (342), Etaurisano (368), Mwurzburg (369) and Yorzinuovi (391) are indicated (top).
doi:10.1371/journal.pone.0038405.g005
Rare a1-Antitrypsin Variants and Polymerization
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38405Supporting Information
Figure S1 Phenotyping of the new AAT variants. IEF
analysis was performed on plasma from the heterozygous carriers
of the new AAT variants, comparing them with plasma of known
phenotype in a pH gradient of 4,2–4,9. The arrow shows the
major band of the Etaurisano variant. The asterisk shows the
major band of Yorzinuovi.
(TIF)
Information S1 Clinical data. Supplementary clinical in-
formation on the index cases carrying the Mpisa, Etaurisano and
Yorzinuovi AAT alleles.
(DOC)
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